GSK Sales Rise 5%, Beat Third-Quarter Estimates

GSK released third-quarter results on Oct. 28, 2026. Sales rose 5% at constant exchange rates to £8.89 billion, beating expectations of £8.84 billion, and 4% at actual rates. Core earnings per share were 54.6 pence versus consensus of 50.4 pence. Core operating profit rose 5% at constant currencies to £3.08 billion. Reported operating profit fell 16% to £2.13 billion after a £328 million restructuring charge tied to the Accelerate Growth cost-savings programme. Specialty medicines sales rose 15% to £3.9 billion. Vaccines revenue declined 2% to £2.6 billion. Luke Miels said in a statement: "GSK has delivered another strong quarter, with our key growth drivers and new launches performing well. We remain focused on operational delivery, execution and accelerating R&D." GSK reaffirmed its full-year sales growth outlook of 3% to 5% and core operating profit and earnings-per-share growth outlooks of 7% to 9%, while saying research and development spending is expected to grow significantly faster than sales. WHAT'S CONTESTED: The record shows no dispute among sources on the sales, profit, charge or guidance figures. Rated coverage was 1 left, 2 center and 0 right. The left-rated AOL piece led on topping estimates as new medicines drive growth while the company keeps its outlook.